ENDRA Life Sciences Inc. (NASDAQ:NDRA) Short Interest Update

ENDRA Life Sciences Inc. (NASDAQ:NDRA) was the recipient of a significant decline in short interest during the month of July. As of July 15th, there was short interest totaling 27,635 shares, a decline of 34.4% from the June 30th total of 42,119 shares. Currently, 2.4% of the company’s stock are sold short. Based on an average trading volume of 36,764 shares, the days-to-cover ratio is presently 0.8 days.

ENDRA Life Sciences Stock Performance

Shares of NDRA stock opened at $4.71 on Friday. The stock’s 50 day simple moving average is $4.99 and its 200 day simple moving average is $4.61. The company has a market capitalization of $5.99 million, a price-to-earnings ratio of -0.58 and a beta of -0.06. ENDRA Life Sciences has a twelve month low of $2.96 and a twelve month high of $9.85.

ENDRA Life Sciences (NASDAQ:NDRA) last announced its quarterly earnings results on Friday, May 15th. The company reported ($1.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.14. On average, analysts forecast that ENDRA Life Sciences will post -4.11 EPS for the current fiscal year.

Hedge Funds Weigh In On ENDRA Life Sciences

A hedge fund recently bought a new stake in ENDRA Life Sciences stock. Altium Capital Management LLC purchased a new stake in ENDRA Life Sciences Inc. (NASDAQ:NDRA) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences comprises 0.9% of Altium Capital Management LLC’s holdings, making the stock its 17th largest position. Altium Capital Management LLC owned approximately 6.92% of ENDRA Life Sciences as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 1.19% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on NDRA shares. Weiss Ratings restated a “sell (e+)” rating on shares of ENDRA Life Sciences in a research note on Friday, July 17th. Ascendiant Capital Markets reduced their price objective on shares of ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, June 1st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $25.00.

About ENDRA Life Sciences

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.